When a new agent is introduced into therapeutics it is important to obtain reliable comparison with existing drugs. Examination of the published reports on guanethidine, methyldopa, and bethanidine provides only an approximate estimate of their comparative merits. Most reports indicate that about 70% of patients achieve reasonable control of their blood pressure with each drug. However, the conditions of the trials varied in many respects, such as levels of blood pressure accepted as good and fair control, the severity of the hypertension in the patients treated, and the clinic routine. In addition, it is difficult to obtain a clear idea of the acceptability of these drugs by patients and of the incidence of side-effects. It was with these factors in mind that, following our initial studies with bethanidine (Johnston, Prichard, and Rosenheim, 1962, 1964) , we designed a formal trial to compare bethanidine with the established drugs guanethidine and methyldopa.
When a new agent is introduced into therapeutics it is important to obtain reliable comparison with existing drugs. Examination of the published reports on guanethidine, methyldopa, and bethanidine provides only an approximate estimate of their comparative merits. Most reports indicate that about 70% of patients achieve reasonable control of their blood pressure with each drug. However, the conditions of the trials varied in many respects, such as levels of blood pressure accepted as good and fair control, the severity of the hypertension in the patients treated, and the clinic routine. In addition, it is difficult to obtain a clear idea of the acceptability of these drugs by patients and of the incidence of side-effects. It was with these factors in mind that, following our initial studies with bethanidine (Johnston, Prichard, and Rosenheim, 1962, 1964) , we designed a formal trial to compare bethanidine with the established drugs guanethidine and methyldopa.
Patients.-Details of the 30 patient-volunteers completing the trial are summarized in Table I ; four of the original 34 patients were withdrawn (see below). The patients were selected solely by the criteria that it was thought necessary to treat them with potent hypotensive drugs and that they were able to attend regularly. All except one patient were on potent drugs before the trial-14 on bethanidine, 11 on guanethidine, and 4 on methyldopa.
Method Summary of Trial
A within-patient comparison was designed in which each patient received bethanidine, guanethidine, and methyldopa. These drugs were prepared in identical capsules and were given in random order, the randomization being stratified according to the treatment the patient was receiving before the trial.
Patients were seen at two-weekly intervals during the trial (except for the intrusion of their holidays) under identical clinic conditions. At each visit patients were first asked standard questions and their symptoms recorded by physician A (B. N. P.), who knew the treatment they were receiving. Blood pressures were then taken by physician B (A. W. J.), who was unaware of the treatment being administered. Physician B gave instruction to physician A whether to increase, decrease, or continue at the present dosage of drug.
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After careful consideration it was not thought desirable for physician A to be " blind." Safe and reasonably rapid adjustment of the dose was essential in order to avoid exposing the patients to unnecessary risk, and as the duration of action of the drugs varies different dose schedules have to be followed. The final decision on instructions to adjust the dose had to be tempered with the knowledge of any side-effects being experienced, most notably symptoms of postural hypotension. In addition, the drugs have several characteristic side-effects which would have permitted physician A in many instances to know which drug was being used.
Previous to the " period of assessment " (see below) on each of the three drugs there was a " run-in period." The run-in period was to enable the dose of each drug to be adjusted to obtain the optimal therapeutic effect. The run-in before the first drugs also served to familiarize the patients with clinic procedure, to ensure that they understood the " weekly symptom record sheet" (see below) which they kept, and, lastly, it went some way to ensure that the greater part of the hypotensive effect of increased interest by the physician became stabilized before the trial proper.
When therapy had been stabilized, control of the blood pressure, and the side-effects, were assessed over a period of three months (period of assessment), during which the patient visited the clinic seven times. During this period only spontaneous complaints of side-effects were recorded, but at the end of each period of assessment direct questions were asked to ensure that nothing was overlooked. The run-in period of the next drug was then begun.
A three-month period of assessment on each drug is not sufficient to enable an opinion to be formed on the comparative merit of these drugs with reference to the development of tolerance or the occurrence of any longer-term side-effects.
Drugs and Dosage
The drugs were presented in identical capsules, half and full strength. The capsule sizes were bethanidine 12.5 and 25 mg., guanethidine 10 and 20 mg., and methyldopa 125 and 250 mg.
Initially patients were started on small doses of the new drug -for example, guanethidine 10 mg. once or twice a day-the dose being gradually increased as required, while the previous drug was concurrently gradually reduced. Except where less than one of the half-strength capsules four times a day of the drug concerned was required to control the blood pressure, a four-times-a-day routine was used for each drug. A three-or four-times-daily schedule is usual with bethanidine and methyldopa, whereas guanethidine is usually given once daily in view of its longer duration of action. The treatment was recorded as a failure when it was not possible to reach even the "-fair" range or else when sufficient drug to produce the desire control of blood pressure resulted in intolerable side-effects.
Clinic Routine
Patients were asked to swallow the capsule(s) whole with water on rising, before the midday meal, before the evening meal, and on going to bed. They kept a weekly symptom record sheet. On this sheet the day was divided up into four periods, space was provided for recording postural symptoms on rising, and, throughout the day, exertional symptoms, headaches, and bowel motions; a space was also provided for patients' comments.
At visits subsequent to the first, patients were seen first by physician A, who recorded their replies to standard questions, recorded any side-effects complained of, and summarized data from the two-weekly symptom record sheet. Physician B then saw the patient in a separate room. He was given the patient's clinical detail sheet and a separate observer sheet for each visit, on which he recorded blood pressures. He did not have available any previous blood pressure readings. Blood pressure was taken one minute and three minutes after the patient had lain on the couch, then again one minute after standing. The supine blood pressures quoted in Table I and subsequent tables are those taken after three minutes on the couch. Pulse rates were recorded before each blood pressure reading. Blood pressure was also taken after ascending and descending 18 stairs. Blood pressures were taken on the London School of Hygiene sphygmomanometer (Rose, Holland, and Crowley, 1964) . This device ensures that the observer is unaware of the actual level of blood pressure at the time he auscultates, and it eliminates digit preference. In the light of the level of blood pressure recorded and the levels defined on the patient's clinical detail sheet, physician B instructed physician A whether to increase or decrease the dose of drug or keep it at its present level. Physician A, who knew the blood pressure readings, followed these instructions unless side-effects prevented this ; the reasons for any deviation from the instructions were recorded.
Patients were seen at the same time (afternoon) at eaoh visit. The capsules were dispensed in the clinic to minimize delay and retain the patients' co-operation. Periods (S.E. 192.3 mg.) in the dose of methyldopa. These increases were not statistically significant.
Levels of Control
The average levels of blood pressure attained during the three-month period of assessment on each drug in each patient are shown in Table I . An example of the actual levels of blood pressure at each visit is shown in Fig. 1 (Case 27). Table  III summarizes the levels of control achieved on each drug, and Table IV gives the average for all the patients on each of the three drugs. The standing diastolic pressures are similar on each drug (Table IV) , as aimed at in planning the trial. Diast.
Syst.
Diast.
Differences between: Bethanidine and guanethidine .. < 0-20 < 0 001 <0-10 < 0 50 < 0-20 < 0 80 Guanethidine and methyldopa .. < 0-001 < 0-001 < 0-001 < 0-80 < 0 90 < 0-025 Methyldopa and bethanidine .. < 0001 < 0-001 < 0-10 < 0 50 < 0 50 < 0-02
Probabilities calculated from differences in logarithms of the blood pressures of patients who received both drugs of the pair being considered.
This picture is not substantially changed by including estimates for the missing observations (in Table I ) derived by the standard method for a randomized block analysis with missing observations. It should be noted that these estimates might be misleading, since the observations were missing owing to intolerance of the drug under test and not to some reason unconnected with the trial. However, the proportion of missing observations is fairly small, and it seems most unlikely that the overall picture could be misleading as a result of this.
Side-effects
The actual side-effects experienced are listed in Table V . They are divided into those complained of spontaneously during the period of assessment and the total, including those elicited by direct questions at the end of the three-month period. In the top part of the In addition, patients were asked at the end of the period of assessment how they had felt overall during the previous three months. They were given four alternatives, in the following order: " well " (scored 5), " only fair " (scored 15), " very well " (scored 0), " ill " (scored 20). The last category was not chosen at all. All these scores were added together, the mean from the patients tolerating the drug concerned being shown in At the end of the trial patients were asked to place in order of preference the capsules they had received. These preferences are summarized in Table VII . They follow the same pattern as seen with the side-effect scores, bethanidine and methyldopa being preferred more often than guanethidine. Drugs were given in random order. Bethanidine was given first 11 times, second 9 times, and third 10 times; guanethidine 10 times for each order; methyldopa first 9 times, second 11 times, and third 10 times. None of the differences reach 5% level of significance. Probabilities calculated as in Table IV. 20 January 1968
Hypertension-Prichard et al. BRITISH MEDICAL JOURNAL 139 lower than for the first, 0.02>P>0.01. When postural and exertional hypotension, headaches, and the patient's own assessment are eliminated (score B) the trend remains but loses its statistical significance. The patients themselves showed a pronounced preference for the third drug (Table VIIIc) . When this apparent reduction in side-effects as the trial proceeds is considered it must also be remembered that four patients could not tolerate the third drug, against only one patient for the first drug.
those on guanethidine, there is a lower systolic pressure whether diastolic pressure is the same or slightly raised. The effect of chlorothiazide on the pulse pressure is summarized in Side-effects A: For differences between 1st and 2nd, and 1st and 3rd drugs, 0-02 > P > 0 01. For differences between 2nd and 3rd, 0-60 > P > 0-50. Side-effects B:
For differences between 1st and 2nd drug, 0-20 > P > 0-10. For differences between 1st and 3rd drug, 0-05 > P > 0-10, For differences between 2nd and 3rd drug, 0-40 > P > 0-50. Probabilities calculated as in Table IV 0-30>P>0-20 0-10>P>0-05 0-20>P>0-10
Effect on Pulse Rate
The effect of the three drugs on the pulse rate is shown in Table XI . The mean of the supine 66, and standing 78, pulse rates on guanethidine was lower than on bethanidine-74 and 89 respectively (in both instances P<0.001); this was not due to differences in blood pressure control (Table IV) . The mean pulse rate on methyldopa (supine 77, standing 93) was more rapid than on guanethidine (in both instances P<0;001). The differences between bethanidine and methyldopa were also significant in the standing position (0.05>P> 0.025). The supine and standing pulse rates in the patients who received bethanidine and guanethidine appear to be slower than in those who had chlorothiazide in addition, but these differences were not significant. The supine pulses on methyldopa with or without chlorothiazide showed little difference, and there was no difference at all in the standing pulse rates on methyldopa in the presence or absence of chlorothiazide. Supine and standing pulse rates on guanethidine for all patients significantly slower than on bethanidine or methyldopa; in all instances P < 0-001. Bethanidinc supine rate not significantly slower than on snethyldopa, 0-20> P > 0-10; standing rate significantly slower than on methyldopa, 0-05 > P > 0-025. Probabilities calcuated as in Table IV (Fig. 2) ; with bethanidine and methyldopa there were 12 out of a possible 24 patients (Fig. 3) ; and with methyldopa and guanethidine 17 out of a possible 23 patients (Fig. 4) . In Figs. 2 to 4 are plotted the per cent. ratio of the mean erect over the mean supine blood pressure (diastolic plus one-third of pulse pressure), and mean exercise over the mean supine blood pressure. The ratio is calculated from the grand mean of the average blood pressures of each patient over the three-month period of assessment. It can be seen (Fig. 2) that there is a slightly larger postural and exercise drop in blood pressure from bethanidine than from guanethidine, but this small difference is statistically significant. Figs. 3 and 4 show that while methyldopa produced some postural and exercise hypotension it was considerably less than that from bethanidine or guanethidine. In these patients the presence or absence of chlorothiazide in the regimen did not affect the differences between the three drugs. the standing position than either bethanidine or methyldopa. The pulse rate on bethanidine appears slower than on methyldopa, but the differences are not significant. The same changes are seen when those patients who received chlorothiazide in addition to one or both of the drugs being compared are excluded. Probabilities calculated as in Table IV. The side-effect scores in these patients (Table XIIc) show that there is a significant preference for bethanidine (mean 15.1) against guanethidine (mean 23.7), and for methyldopa (mean 14.4) against guanethidine (mean 20.5). There is no significant difference in the side-effect scores in patients achieving similar control of blood pressure on bethanidine (mean 12.8) and methyldopa (mean 14). A similar trend is seen when chlorothiazide is excluded from the comparison. Excludingchlorothiazide n =7 8-3 S.E. 1-04 9-6 S.E. 1-59 r P > Methyldopa Guanethidine All patients n = 17 n 14-4 S.E. 1-87 20-5 S.E. 1-97 0-005 > P > 0 001 Excluding chlorothiazide n =10 12-4 S.E. 2-18 20-9 S.E. 3-01 0-02 > P > 0-01 Probabilities calculated as in Fable IV.
Weight
Patients were weighed at each visit. There was no significant difference in the average weights on bethanidine, guanethidine, and methyldopa. (Lowther and Turner, 1963) . A similar pattern is seen in many trials with methyldopa -for instance, 42% of 33 patients (Cannon, Whitlock, Morris, Angers, and Laragh, 1962) , 54% of 59 patients (Dollery and Harington, 1962) , 67% of 69 patients (Hamilton and Kopelman, 1963) , 49% of 100 patients (Johnson, Kitchin, Lowther, and Turner, 1966) . These last authors compared the fall of blood pressure in 37 patients on methyldopa with that in 66 patients of similar severity on guanethidine and found no significant difference between the drugs.
Previous evidence thus indicates that bethanidine, guanethidine, and methyldopa are probably similar in their ability to control the blood pressure. The present study does not show any significant differences (Tables III and IV) (1965) found that the three drugs produced similar average reduction of blood pressure.
The levels of blood pressure control achieved in our patients are lower on all three drugs than in some previously reported series. Our cases were not of less severity than those in many of the previous studies. It seems probable that lower blood pressure readings were obtained in this trial because the patients were thoroughly familiar with the clinic routine and were seen fortnightly by the same physician, who increased the dosage until either the desired blood pressure was reached or unacceptable side-effects occurred.
Postural and Exercise Hypotension
When a close comparison is made between the pharmacological effects of hypotensive drugs with not very dissimilar modes of action doses that produce equivalent physiological effects are best given before any comparison is made.
Consideration of those patients whose mean standing diastolic blood pressure over the three-month period was controlled to within 10 mm. Hg and was also within the range of 80 to 100 mm. Hg (Figs. 2, 3 , and 4) shows: (1) that, when tolerated, methyldopa produces significantly less of a postural and exercise drop in blood pressure than guanethidine or bethanidine, or that for a given standing diastolic pressure on methyldopa the supine pressure is lower; and (2) that guanethidine produces a slightly but significantly smaller drop on posture and exercise than does bethanidine. Similar changes occur if the grand mean of all the patients is taken (Table IV) . Smirk (1963a) Goldberg and Zimmerman (1963) , reviewing the earlier work on guanethidine and methyldopa, concluded: " Methyldopa has a greater effect than guanethidine on supine pressure." In the first randomized comparison under defined conditions (a within-patient comparison) Oates et al. (1965) found that methyldopa produced less of a postural drop in blood pressure than guanethidine (P<0.05); they also found that pargyline was similar to guanethidine in this regard.
The findings of the present trial confirm this difference between methyldopa and guanethidine, and also that after erect exercise there is a larger fall of blood pressure in patients on guanethidine than on methyldopa. This difference was still seen when analysis was confined to patients whose standing diastolic pressure was controlled to similar levels. Methyldopa is thought to be converted to a-methylnoradrenaline, and this substance may then act as a false transmitter at the nerve endings, replacing noradrenaline (Day and Rand, 1963 ). a-Methylnoradrenaline has some stimulatory action, though much less than noradrenaline, so the effect of nerve stimulation may be inhibited without being completely blocked. This is in accord with the finding that when the supine blood pressure is reduced by methyldopa (a position where there is a low level of sympathetic nerve activity), on changing to the standing position (where a higher level of sympathetic activity is required to maintain the blood pressure) the effect of impulses is not so fully inhibited as with bethanidine or guanethidine. Hence there is not so great a postural drop in blood pressure as with many other drugs giving an equivalent degree of block at lower levels of sympathetic nerve activity.
None of the previous trials has compared methyldopa and bethanidine. Our finding that, like guanethidine, bethanidine produces greater postural and exercise hypotension than methyldopa is not surprising, as the mode of action of bethanidine (Boura and Green, 1963) has many similarities to that of guanethidine.
Likewise there has been little published evidence comparing the effect of posture and exercise in patients receiving bethanidine and guanethidine, though the statement was made by Wilson, Long, and Jagoe (1965) : " In our opinion, postural hypotension is more marked with bethanidine sulphate than with bretylium or guanethidine," though no evidence was quoted. Gifford (1965) did not find any difference in " symptomatic orthostatic hypotension " between bethanidine and guanethidine. Our finding that bethanidine produces a slightly greater fall in blood pressure on standing and after erect exercise than guanethidine is statistically significant, but in view of the smallness of this difference is not of clinical importance.
This difference, interestingly, was predicted by Boura and Green (1963) from animal experiments.
Guanethidine preferentially abolished the response to low frequency of sympathetic nerve stimulation to the cat's nictitating membrane but did not alter the slope of the curve relating frequency of sympathetic nerve stimulation to the resultant contraction of the cat nictitating membrane (Boura and Green, 1962) . Bethanidine, however, depressed the slope-that is, relatively greater blockade at higher rates of stimulation than guanethidine, with responses to a low rate of stimulation inhibited relatively less (Boura and Green, 1963 (Table  XI) , this difference not being due to differences in blood pressure control (Table IV) . This same difference is also seen when the standing diastolic pressure is controlled to similar levels in each patient (Table XIIb) . It is also possible that bethanidine produces greater slowing than methyldopa; the difference is significant when all patients are considered in the standing position (Table XI) , but this difference did not reach accepted levels of significance in those patients achieving similar levels of blood pressure control ( Table XIIb) . The reason for these findings is not clear, but it is suggestive that there are differences in the relative effects of these drugs on the sympathetic supply to blood vessels, arteries, and/or veins from that to the heart.
Chlorothiazide
Those patients who received chlorothiazide in addition to their primary drug achieved blood pressure control similar to that of patients not receiving chlorothiazide (Table IX) . There seems to be a tendency for patients whose blood pressure is controlled with chlorothiazide in addition to bethanidine, guanethidine, or methyldopa to have a lower pulse pressure than those not having chlorothiazide in addition (Table X) . It is well known that the treatment of hypertension with chlorothiazide (Freis, Wanko, Wilson, and Parrish, 1958) and other diuretics (Cranston, Juel-Jensen, Semmence, Handfield Jones, Forbes, and Mutch, 1963) often produces a greater reduction in systolic than in diastolic pressure, though this might be largely ascribed to an effect of general lowering of the blood pressure.
This cannot be the explanation when the pulse pressure in patients receiving chlorothiazide is lower than in those not having chlorothiazide when blood pressure is controlled to a similar level in both groups. Long-term administration of chlorothiazide reduces peripheral resistance and does not reduce the cardiac output (Conway and Lauwers, 1960) ; a lowered peripheral resistance might be contributory to the reduced pulse pressure.
Though the differences were not significant, there was a tendency for the pulse rate to be faster in those who received chlorothiazide in addition to bethanidine or guanethidine (Table XI) ; this could at least account for some of the reduced pulse pressure on chlorothiazide. However, while the standing pulse on methyldopa was the same with and without chlorothiazide, the differences in the pulse pressure (Table X) approached the 5% level of significance.
A within-patient study with and without chlorothiazide is needed to confirm these points and to eliminate the possibility that the differences in those patients receiving chlorothiazide were not due to chlorothiazide but to whatever factors that caused us to administer chlorothiazide to facilitate control of the blood pressure.
Side-effects: Overall Assessment Table V lists side-effects which were given an arbitrary score in an effort to present some composite picture of the comparative effect of the drugs. As is well known, direct questions elicit many more side-effects, so it seemed reasonable to score an additional 2 for a side-effect if it was mentioned spontaneously. The effect of variation between patients was reduced by the within-patient design, and randomization of There was no significant difference in the incidence of headaches with the three drugs. For patients who had an average of one or more headaches a week the figures were 27 %, 14%, and 29% on bethanidine, guanethidine, and methyldopa respectively. Lowther and Turner (1963) reported headaches in 30% of their 70 patients on guanethidine, but a large number of trials do not mention the occurrence of headaches-for example, Oates et al. (1965) in their comparative study. Smirk (1963b) makes the comment that headaches are seen more often on bethanidine than on other hypotensive drugs, but figures are not quoted.
Bowels
Fifty-two per cent. of our patients tolerating the drug complained of diarrhoea spontaneously while on guanethidine ; with direct questioning the incidence was 66%. For bethanidine the incidence was 7% and 10% respectively, and for methyldopa 8 % and 13 %. In addition, one patient could not tolerate guanethidine because of diarrhoea; as happened to two with methyldopa, one withdrawing from the trial for this reason. Other trials confirm the very high incidence of diarrhoea on guanethidine-for example, 61 % of patients (Lowther and Turner, 1963) ; the low frequency on methyldopa-for example, 4% (Johnson et al., 1966) ; while one previous trial recorded one patient who had diarrhoea with bethanidine (Johnston et al., 1964) .
While there is no doubt about the incidence of diarrhoea with guanethidine, it seems probable that methyldopa produces more diarrhoea than does bethanidine, and it can be troublesome enough to warrant withdrawal of the drug.
Constipation occurred in four (13 %) of our patients on bethanidine, one on guanethidine, none on methyldopa. Examination of previous trials indicates that constipation is most unusual with methyldopa or guanethidine. Wilson et al. (1965) report one patient out of 43 on bethanidine, while Smirk (1963b) records instances of mild constipation. It seems probable that bethanidine is more likely to produce constipation than are the other drugs.
C.N.S. Side-effects
Seventy-five per cent. of patients spontaneously complained of various degrees of tiredness on methyldopa, as against 10% on bethanidine and 17% on guanethidine. Direct questioning elicited this symptom in 83%, 50%, and 52% respectively. In addition, one patient could not tolerate methyldopa at all because of tiredness. Oates et al. (1965) report drowsiness in 47% of their patients on methyldopa, but in none of those on guanethidine. Tiredness from use of bethanidine has been reported by Gifford (1965) Pickens, 1962 ; Smirk, 1963b; Johnston et al., 1964; Wilson et al., 1965) . It is unusual with guanethidine; was not seen in the trials of Page and Dustan (1959) , Leishman et al. (1959 ), Bauer et al. (1961 , or Lowther and Turner (1963) ; but was described as common by Dollery et al. (1960) . In contrast, a relatively high incidence of tiredness, temporary or permanent, has been seen in trials with methyldopa-for example, 41 % (Johnson et al., 1966) and " most " (Hamilton and Kopelman, 1963) .
Dreams were complained of spontaneously in four (17%) patients on methyldopa; with direct questioning the incidence was 38 %. No patient mentioned dreams spontaneously on bethanidine or guanethidine, though the incidence was 10n% and 14% with direct questioning. Dreams were reported by Johnson et al. (1966) in 4 of their 100 patients on methyldopa and Smirk (1963a) in one patient.
Marked depression necessitating immediate withdrawal of the drug occurred in two patients on methyldopa; in both it quickly subsided after treatment was stopped. Mild depression was elicited on direct questioning of two patients (7%) on bethanidine, six (21%) on guanethidine, and three (13%) on methyldopa. This confirms previous trials which show that depression is more troublesome with methyldopa (4 out of 100 patients (Johnson et al., 1966) , 3 out of 69 patients (Hamilton and Kopelman, 1963) , 5 out of 47 (Smirk, 1963a) , 2 out of 59 (Dollery and Harington, 1962) ) than with guanethidine (4 out of 28 with one suicide (Bauer et al., 1961) , 2 out of 80 (Dollery et al., 1960) , none out of 75 (Lowther and Turner, 1963) , none out of 25 (Leishman et al., 1959) ). Previous trials of bethanidine have not reported any cases attributed to the drug, though Gifford (1965) mentions two incidental instances.
Side-effects of Sympathetic Blockade
The greater incidence of symptoms attributable to excessive hypotension has been discussed above. Other side-effects attributable to sympathetic neurone block also show a lower incidence with methyldopa. This can be seen in Table V from the relative incidence of nasal obstruction or failure of ejaculation. The reports quoted above confirm this differential incidence. There was also less nocturia on methyldopa.
Other Side-effects
The incidence of shortness of breath was similar on all three drugs, and the weights of the patients were not affected by the drugs. However, ankle swelling was a complaint of one patient while on methyldopa, and with direct questions a second patient reported it. Ankle swelling has been reported with methyldopa (Dollery and Harington, 1962; Hamilton and Kopelman, 1963; Johnson et al., 1966) ; it is uncommon with guanethidine; and has not yet been reported on bethanidine.
Conclusions and Summary
In those patients who tolerated the drugs the control of the blood pressure on each drug was very similar (Tables III and   IV) .
If a patient is able to tolerate methyldopa control of the blood pressure is more physiological, there being less postural and exercise hypotension on that drug (Tables IV and IX; Figs. 3 and 4). However, 6 of the 30 patients could not tolerate methyldopa, and one additional patient withdrew from the trial because of diarrhoea. The acceptability to the 24 patients tolerating methyldopa was the same as for all 30 patients on bethanidine, as judged by side-effect scores; and by patients' preference (Table VII) differences in favour of bethanidine were not significant (Tables VI and XIb) . Tiredness is the most characteristic and troublesome side-effect with methyldopa, patients often not realizing how tired they are until they change to a different regimen.
Bethanidine and guanethidine are qualitatively similar in their side-effects with the exception of the very high incidence of diarrhoea on guanethidine. As shown by side-effect scores (Tables VI and XIIc) or patients' preference (Table VII) , guanethidine was much less popular with patients than the other two drugs. Bethanidine also differs from guanethidine in having a much shorter duration of action (Johnston et al., 1964) . Guanethidine does produce less postural and exercise hypotension, but this difference is slight (Tables IV and XIIa; Fig. 2 ) and might not be regarded as of much clinical importance, though it achieves high statistical significance. It might be felt that the higher incidence of side-effects from guanethidine outweighs this advantage. HyetninPihr e3t al.
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In summary, methyldopa, provided it is tolerated, produces the best all-round blood pressure control of these three drugs, but 20% of our patients could not tolerate it. Bethanidine was tolerated by all patients, but brought slightly greater postural and exercise hypotension than guanethidine, which, however, produced the largest number of side-effects.
